John Robinson - Cogent Biosciences Chief Officer
| COGT Stock | USD 7.16 0.13 1.78% |
Insider
John Robinson is Chief Officer of Cogent Biosciences
| Age | 50 |
| Address | 275 Wyman Street, Waltham, MA, United States, 02451 |
| Phone | 617 945 5576 |
| Web | https://www.cogentbio.com |
John Robinson Latest Insider Activity
Tracking and analyzing the buying and selling activities of John Robinson against Cogent Biosciences stock is an integral part of due diligence when investing in Cogent Biosciences. John Robinson insider activity provides valuable insight into whether Cogent Biosciences is net buyers or sellers over its current business cycle. Note, Cogent Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Cogent Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
John Robinson over six months ago Acquisition by John Robinson of 300000 shares of Cogent Biosciences at 4.63 subject to Rule 16b-3 |
Cogent Biosciences Management Efficiency
The company has return on total asset (ROA) of (0.5378) % which means that it has lost $0.5378 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9954) %, meaning that it created substantial loss on money invested by shareholders. Cogent Biosciences' management efficiency ratios could be used to measure how well Cogent Biosciences manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.82 in 2025. Return On Capital Employed is likely to drop to -1.06 in 2025. At this time, Cogent Biosciences' Total Current Liabilities is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 22 M in 2025, whereas Liabilities And Stockholders Equity is likely to drop slightly above 206 M in 2025.Similar Executives
| Showing other executives | INSIDER Age | ||
| LCSW BA | Verona Pharma PLC | 55 | |
| Paul Stone | Ideaya Biosciences | 60 | |
| Anjali Ganguli | Syndax Pharmaceuticals | 47 | |
| MD MBA | Kalvista Pharmaceuticals | 52 | |
| Sunil MD | Sana Biotechnology | 54 | |
| Melissa MBA | Zentalis Pharmaceuticals Llc | 45 | |
| Jeffrey Trigilio | Cullinan Oncology LLC | 40 | |
| Kevin Bunker | Zentalis Pharmaceuticals Llc | 52 | |
| John Moriarty | Olema Pharmaceuticals | 56 | |
| Alexander Nolte | Syndax Pharmaceuticals | 51 | |
| Richard Heyman | Syndax Pharmaceuticals | 68 | |
| Thomas Doyle | Kura Oncology | 54 | |
| Sanj Patel | Kiniksa Pharmaceuticals | 56 | |
| PharmD Faltaos | Olema Pharmaceuticals | N/A | |
| John McKune | Kalvista Pharmaceuticals | 48 | |
| Carla Poulson | Mersana Therapeutics | N/A | |
| Simon MBBS | Keros Therapeutics | 54 | |
| Nina Church | Verona Pharma PLC | N/A | |
| Thomas MBA | Kalvista Pharmaceuticals | 49 | |
| Matthew Casbon | Verona Pharma PLC | N/A | |
| Jennifer Lachey | Keros Therapeutics | 51 | |
Management Performance
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.54 |
Cogent Biosciences Leadership Team
Elected by the shareholders, the Cogent Biosciences' board of directors comprises two types of representatives: Cogent Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cogent. The board's role is to monitor Cogent Biosciences' management team and ensure that shareholders' interests are well served. Cogent Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cogent Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Sara Saltzman, VP Affairs | ||
| Jessica MD, Chief Officer | ||
| Brad Fell, Senior Chemistry | ||
| Rachael MD, VP Development | ||
| Andrew MBA, CEO President | ||
| Christi Waarich, Senior Relations | ||
| Brad Barnett, Chief Officer | ||
| Erin Schellhammer, Chief Officer | ||
| John Robinson, Chief Officer | ||
| Evan JD, Chief Secretary | ||
| Dana PharmD, Senior Officer |
Cogent Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cogent Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.0 | ||||
| Return On Asset | -0.54 | ||||
| Current Valuation | 681.77 M | ||||
| Shares Outstanding | 113.85 M | ||||
| Shares Owned By Insiders | 0.15 % | ||||
| Shares Owned By Institutions | 99.85 % | ||||
| Number Of Shares Shorted | 10.8 M | ||||
| Price To Earning | (5.03) X | ||||
| Price To Book | 5.77 X | ||||
| Price To Sales | 1,321 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cogent Stock Analysis
When running Cogent Biosciences' price analysis, check to measure Cogent Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cogent Biosciences is operating at the current time. Most of Cogent Biosciences' value examination focuses on studying past and present price action to predict the probability of Cogent Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cogent Biosciences' price. Additionally, you may evaluate how the addition of Cogent Biosciences to your portfolios can decrease your overall portfolio volatility.